A5053161165- Venous Thromboembolism Diagnosis and Management
- Heparin-Induced Thrombocytopenia and Thrombosis
- Atrial Fibrillation Management and Outcomes
- Blood Coagulation and Thrombosis Mechanisms
- Platelet Disorders and Treatments
- Antiplatelet Therapy and Cardiovascular Diseases
- Acute Myocardial Infarction Research
- Systemic Lupus Erythematosus Research
- Intramuscular injections and effects
- Peripheral Artery Disease Management
- Cardiac Arrhythmias and Treatments
- Central Venous Catheters and Hemodialysis
- Cardiovascular Issues in Pregnancy
- Drug-Induced Adverse Reactions
- Case Reports on Hematomas
- Diagnosis and Treatment of Venous Diseases
- Monoclonal and Polyclonal Antibodies Research
- Vascular Procedures and Complications
- Intracerebral and Subarachnoid Hemorrhage Research
- Hemophilia Treatment and Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cardiac, Anesthesia and Surgical Outcomes
- Acute Ischemic Stroke Management
- Vascular anomalies and interventions
- Blood Pressure and Hypertension Studies
Cardiovascular Center Bethanien
2016-2025
Taipei Medical University Hospital
2023
Hospital Universitario Araba
2023
National Defense Medical Center
2023
Agaplesion Bethanien Krankenhaus
2017-2019
Agaplesion Markus Hospital
2019
Angiologica (Italy)
2018
Goethe University Frankfurt
2009-2018
University Hospital Frankfurt
2009-2018
Ärztliche Gesellschaft zur Gesundheitsförderung e.V
2018
This guidance document was prepared on behalf of the International Council for Standardization in Haematology (ICSH) providing haemostasis-related documents clinical laboratories. inaugural coagulation ICSH developed by an ad hoc committee, comprised international and laboratory direct acting oral anticoagulant (DOAC) experts. The committee consensus recommendations measurement DOACs (dabigatran, rivaroxaban, apixaban edoxaban), which would be germane laboratories assessing DOAC...
Background— Critical limb ischemia due to peripheral arterial occlusive disease is associated with a severely increased morbidity and mortality. There no effective pharmacological therapy available. Injection of autologous bone marrow-derived mononuclear cells (BM-MNC) promising therapeutic option in patients critical ischemia, but double-blind, randomized trials are lacking. Methods Results— Forty were included multicenter, phase II, randomized-start trial receive either intraarterial...
Platelet-activating anti-platelet factor 4 (PF4)/heparin antibodies and anti-PF4 cause heparin-induced thrombocytopenia (HIT) vaccine-induced immune thrombosis (VITT), respectively. Diagnostic treatment considerations differ somewhat between HIT VITT. We identified patients with without proximate heparin exposure or adenovirus-based vaccination who tested strongly positive by PF4/polyanion enzyme-immunoassays negative/weakly platelet activation (HIPA) test but PF4-induced (PIPA) (ie,...
Summary. The frequency of heparin‐induced thrombocytopenia (HIT) varies between different clinical treatment settings and remains unknown for patients treated with unfractionated (UFH) or low‐molecular‐weight heparin (LMWH) because deep vein thrombosis. In this multicentre, open‐label study, 1137 thrombosis were randomly assigned to UFH 5–7 d, reviparin, a LMWH, d (short‐treated group) reviparin 28 (long‐treated group). Heparin‐platelet factor 4 antibodies (HPF4‐A) determined on 21....
Summary It was the objective of this study to quantify effects rivaroxaban administration on global coagulation parameters associated with routine clinical procedures, we collected plasma samples from patients undergoing major orthopaedic surgery receiving at various time points after drug administration. Forty-seven received (10 mg daily) for venous thromboembolism prophylaxis. Blood were four different points: A) before surgery; B) day 4–5 (steady state rivaroxaban); C) 2 hours (h) and D)...
Summary Antithrombin (AT) is the most important physiological inhibitor of coagulation proteases. It activated by glycosaminoglycans such as heparin. Hereditary antithrombin deficiency a rare disease that mainly associated with venous thromboembolism. So far, more than 200 different mutations in gene (SERPINC1) have been described. The aim our study was to characterise molecular background large cohort patients AT deficiency. Mutation analysis performed direct sequencing SERPINC1 272...
Summary Rivaroxaban is a direct factor Xa inhibitor, which can be monitored by anti-factor chromogenic assays. This ex vivo study evaluated different assays for accurate determination of rivaroxaban levels. Eighty plasma samples from patients receiving (Xarelto®) 10 mg once daily and 20 healthy volunteers were investigated using one assay with the addition exogenous antithrombin two without antithrombin. Two lyophilised calibration sets used each (low concentration set: 0, 14.5, 59.6 97.1...
Little is known about the incidence and causes of heparin-induced skin lesions. The 2 most commonly reported lesions are immune-mediated thrombocytopenia delayed-type hypersensitivity reactions.We prospectively examined consecutive patients who received subcutaneous heparin (most often enoxaparin or nadroparin) for presence If such were identified, we performed a biopsy, platelet count measurements, antiplatelet-factor 4 antibody allergy testing.We enrolled 320 patients. In total, 24 (7.5%,...
Thrombophilia is a well-established risk factor for venous thromboembolic event (VTE), and it has been proposed that hereditary thrombophilia may substantially contribute to the development of VTE in young patients. We aimed analyse prevalence with special regard age manifestation. The study cohort consisted 1490 patients (58% females) median 43 years at time their first VTE. At least one thrombophilic disorder was identified 50·1% probability detecting declined significantly advancing (from...
Anticoagulation with dabigatran etexilate (DE) has a favorable risk-to-benefit profile for the prevention of ischemic events in patients atrial fibrillation compared to warfarin. Whereas warfarin constitutes strong contraindication thrombolysis, it is unclear whether anticoagulated DE can be thrombolysed. We risk thrombolysis-associated hemorrhagic transformation (HT) after pretreatment or mouse model stroke.Thirty-nine C57BL/6 mice were pretreated orally 75 mg/kg DE, 112.5mg/kg 2mg/kg...
Global coagulation assays display variable effects at different concentrations of rivaroxaban. The aim this study is to quantify the ex vivo low-dose rivaroxaban on thrombophilia screening and factor activities based administration time, show how mask possible interferences. Plasma samples from 40 patients receiving 10 mg daily were investigated measure clotting II, V, VII, VIII, IX, XI, XII XIII; protein C- S-levels; lupus anticoagulants; anticardiolipin IgG IgM; D-dimer, heparin-platelet 4...
Mutations in the antithrombin (AT) gene can impair capacity of AT to bind heparin (AT deficiency type IIHBS), its target proteases such as thrombin (type IIRS), or both IIPE). Type II deficiencies are almost exclusively caused by missense mutations, whereas I originate from null mutations. In a retrospective cohort study, we investigated impact mutation and on manifestation thromboembolic events 377 patients with hereditary (133 our own cohort, 244 reported literature). Carriers mutations...
Background: Major bleeding or emergency surgery are the most frequently observed situations in patients anticoagulated with vitamin K antagonists (VKAs) direct oral anticoagulants (DOACs). The restart of anticoagulation after these is a therapeutic dilemma. Methods: prospective RADOA registry an observational, noninterventional multicenter that documents management severe treated VKAs DOACs. In this substudy, we analyzed time point, type, and dosage anticoagulant resumption situations....